The proliferation of breast cancers and ovarian cancers usually involves estrogen receptor (ER) pathway in addition to being driven through mitogen-activated protein kinases (MAPKs) signal transduction.1,2 This pathway will be active when estrogen binds to and activate its receptor, which further activates the expression of genes necessary to spur cell cycle progression. The gene discussed is ESR1; the disease is ovarian carcinoma.